Literature DB >> 9071263

Burden of migraine: societal costs and therapeutic opportunities.

R B Lipton1, W F Stewart, M von Korff.   

Abstract

Migraine imposes an enormous health burden on individual headache sufferers and on society. The condition affects about 18% of women and about 6% of men across their lifespan. Because prevalence peaks during the most productive years, between the ages of 25 and 55, migraine is an important cause of lost work time. Despite the widespread underdiagnosis and undertreatment of migraine, health care costs for the condition are considerable. Add to this the indirect costs, in the form of absenteeism and reduced productivity at work, and the overall burden of migraine becomes apparent. Work loss is not uniformly distributed, with the most disabled half of migraineurs accounting for more than 80% of all work loss. Although improvements in health care delivery for migraine may increase direct cost (i.e., drug or medical care), this may be offset by savings in indirect costs (i.e., reduced and lost productivity).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071263     DOI: 10.1212/wnl.48.3_suppl_3.4s

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Clinical features of unilateral headaches beyond migraine and cluster headache and their response to indomethacin.

Authors:  Stefan Seidel; Doris Lieba-Samal; Marion Vigl; Christian Wöber
Journal:  Wien Klin Wochenschr       Date:  2011-07-26       Impact factor: 1.704

Review 2.  Burden of tension-type headache.

Authors:  Marc E Lenaerts
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 3.  The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.

Authors:  Wayne N Burton; Stephen H Landy; Kristen E Downs; M Chris Runken
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

4.  The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication.

Authors:  Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin
Journal:  Headache       Date:  2015-10-16       Impact factor: 5.887

5.  The migraine work and productivity loss questionnaire: concepts and design.

Authors:  D J Lerner; B C Amick; S Malspeis; W H Rogers; N C Santanello; W C Gerth; R B Lipton
Journal:  Qual Life Res       Date:  1999-12       Impact factor: 4.147

Review 6.  Psychological risk factors in headache.

Authors:  Robert A Nicholson; Timothy T Houle; Jamie L Rhudy; Peter J Norton
Journal:  Headache       Date:  2007-03       Impact factor: 5.887

Review 7.  Headache in primary care: how important is diagnosis to management?

Authors:  Norma O'Flynn; Leone Ridsdale
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

Review 8.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.

Authors:  Stephen Landy; Sarah E DeRossett; Alan Rapoport; John Rothrock; Michael H Ames; Susan A McDonald; Steven P Burch
Journal:  MedGenMed       Date:  2007-06-07

10.  Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Authors:  L C Newman; R K Cady; S Landy; P O'Carroll; W J Kwong; S P Burch; A C Nelsen; S A McDonald
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.